Innate Pharma S.A. (IPHA) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Veraxa Biotech (VRXA) over the past year, losing 26.4% versus a loss of 89.6%. Innate Pharma S.A. is the larger company by market cap ($181.0 million vs $178.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | VRXA |
|---|---|---|
| Share price | $1.62 | $1.26 |
| Market cap | $180.95M | $178.17M |
| 1-day change | +9.46% | +15.60% |
| YTD return | -15.43% | -89.78% |
| 1-year return | -26.37% | -89.58% |
| 5-year return | -74.79% | — |
| EPS (TTM) | $-0.59 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $27.36 |
| 52-week low | $1.17 | $1.04 |
| Distance from 52-week high | -40.22% | -95.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +311.73% | — |
| Average volume | 156.96K | 267.20K |
| Shares outstanding | 111.70M | 141.41M |
| Employees | 120 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed VRXA by 63.2 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
IPHA vs VRXA FAQ
Which is bigger, Innate Pharma S.A. or Veraxa Biotech?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $180.95M compared with $178.17M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, IPHA or VRXA?
IPHA returned -26.37% over the past 12 months, compared with -89.58% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Veraxa Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A. and Biotechnology: Pharmaceutical Preparations for Veraxa Biotech.